|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:actsOn
|
gptkb:NMDA_receptor
|
|
gptkbp:approvedBy
|
gptkb:FDA
treatment-resistant depression
|
|
gptkbp:ATCCode
|
N01AX14
|
|
gptkbp:brand
|
gptkb:Ketanest
gptkb:Esketamine
|
|
gptkbp:CASNumber
|
gptkb:33643-46-8
|
|
gptkbp:chirality
|
true
|
|
gptkbp:discoveredIn
|
1960s
|
|
gptkbp:eliminationHalfLife
|
7-12 hours
|
|
gptkbp:hasEnantiomer
|
(R)-ketamine
|
|
gptkbp:hasGreaterPotencyThan
|
(R)-ketamine
|
|
gptkbp:hasMolecularFormula
|
C13H16ClNO
|
|
gptkbp:hasUNII
|
690G0D6V8H
|
|
gptkbp:isomerOf
|
gptkb:ketamine
|
|
gptkbp:isSchedule
|
gptkb:Schedule_III_(US)
|
|
gptkbp:IUPACName
|
(S)-2-(2-chlorophenyl)-2-(methylamino)cyclohexanone
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Spravato
|
|
gptkbp:metabolism
|
gptkb:ketamine
|
|
gptkbp:molecularWeight
|
237.7 g/mol
|
|
gptkbp:PubChem_CID
|
CHEMBL1201207
444857
|
|
gptkbp:routeOfAdministration
|
intramuscular
intravenous
nasal
|
|
gptkbp:sideEffect
|
gptkb:hallucination
nausea
dissociation
increased blood pressure
|
|
gptkbp:usedAs
|
gptkb:analgesic
gptkb:antidepressant
|
|
gptkbp:usedIn
|
gptkb:veterinary_medicine
human medicine
|
|
gptkbp:bfsParent
|
gptkb:Esketamine
|
|
gptkbp:bfsLayer
|
7
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
(S)-ketamine
|